Braskem S.A.
Braskem S.A. (BAK) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Braskem S.A. (BAK), covering cash flow, earnings, and balance sheets.
Braskem S.A. (BAK) Income Statement & Financial Overview
Analyze Braskem S.A.’s BAK earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $19.46B | $19.15B | $21.27B | $19.07B |
| Cost of Revenue | $18.15B | $18.005B | $19.02B | $17.68B |
| Gross Profit | $1.31B | $1.15B | $2.25B | $1.39B |
| Gross Profit Ratio | $0.07 | $0.06 | $0.11 | $0.07 |
| R&D Expenses | $126.00M | $143.00M | $109.00M | $106.00M |
| SG&A Expenses | $1.18B | $1.31B | $1.17B | $1.03B |
| Operating Expenses | $1.21B | $3.57B | $1.23B | $1.46B |
| Total Costs & Expenses | $19.36B | $21.57B | $20.25B | $19.14B |
| Interest Income | $210.00M | $261.00M | $366.00M | $141.00M |
| Interest Expense | $1.44B | $1.93B | $1.10B | $1.47B |
| Depreciation & Amortization | $1.19B | $1.14B | $1.29B | $1.29B |
| EBITDA | $3.26B | -$5.26B | $1.08B | -$3.24B |
| EBITDA Ratio | $0.17 | -$0.27 | $0.05 | -$0.17 |
| Operating Income | $99.00M | -$2.42B | $1.02B | -$158.00M |
| Operating Income Ratio | $0.005 | -$0.13 | $0.05 | -$0.008 |
| Other Income/Expenses (Net) | $717.00M | -$5.91B | -$2.33B | -$5.84B |
| Income Before Tax | $816.00M | -$8.33B | -$1.31B | -$6.00B |
| Income Before Tax Ratio | $0.04 | -$0.43 | -$0.06 | -$0.31 |
| Income Tax Expense | $184.00M | -$2.44B | -$444.00M | -$2.11B |
| Net Income | $698.00M | -$5.65B | -$593.00M | -$3.73B |
| Net Income Ratio | $0.04 | -$0.29 | -$0.03 | -$0.20 |
| EPS | $0.88 | -$7.08 | -$0.74 | -$4.69 |
| Diluted EPS | $0.88 | -$7.08 | -$0.74 | -$4.69 |
| Weighted Avg Shares Outstanding | $796.97M | $796.97M | $796.97M | $797.21M |
| Weighted Avg Shares Outstanding (Diluted) | $796.97M | $796.97M | $796.97M | $797.21M |
Over the past four quarters, Braskem S.A. demonstrated steady revenue growth, increasing from $19.07B in Q2 2024 to $19.46B in Q1 2025. Operating income reached $99.00M in Q1 2025, maintaining a consistent 1% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $3.26B, reflecting operational efficiency. Net income rose to $698.00M, with EPS at $0.88. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan